THE SCIENCE WORLD
A Monthly e Magazine
ISSN:2583-2212
Popular Article
Oct, 2026 Vol.6(10), 3207-3218

Induction of Hyperglycemia in Laboratory Models by Administration of Epinephrine and Glucagon

G. Rameshkumar, B. Deepika, K. Rajamanickam,T. Sathyabama, S. Jayachandran
Department of Veterinary Physiology, Veterinary College and Research Institute, Namakkal
doi.org/10.5281/ScienceWorld.23447650

1. Introduction

Hyperglycemia, defined as an elevation in blood glucose concentration above the normal physiological range, results from an imbalance between endogenous glucose production and peripheral glucose utilization. Although persistent hyperglycemia is the hallmark of diabetes mellitus, transient hyperglycemia also occurs under physiological conditions such as fasting, exercise, trauma, surgery, and emotional stress due to the release of counter-regulatory hormones. Experimental induction of transient hyperglycemia using these hormones has become an important tool in biomedical research because it enables the investigation of glucose homeostasis without causing irreversible pancreatic β-cell damage (Hall & Hall, 2021).

Among the counter-regulatory hormones, epinephrine and glucagon are the most widely employed for inducing experimental hyperglycemia because of their potent and rapid effects on hepatic glucose production. Unlike chemically induced diabetic models using streptozotocin or alloxan, which permanently impair pancreatic β-cell function, hormone-induced models produce a reversible increase in blood glucose through physiological mechanisms involving glycogenolysis, gluconeogenesis, altered insulin secretion, and reduced peripheral glucose utilization. Consequently, these models are particularly useful for evaluating acute metabolic responses, investigating endocrine regulation of glucose metabolism, and screening antihyperglycemic agents acting on hepatic glucose production or insulin secretion (Vogel, 2008; Brunton et al., 2023).

Experimental evidence has demonstrated that the hyperglycemic effects of epinephrine and glucagon extend beyond direct hepatic glucose production. Gerich et al. (1976) showed that epinephrine stimulates pancreatic glucagon secretion while simultaneously suppressing insulin

release, indicating that catecholamine-induced hyperglycemia results from both direct adrenergic stimulation and indirect endocrine regulation. Similarly, Eigler et al. (1979) demonstrated that physiological concentrations of glucagon and epinephrine act synergistically to enhance hepatic glucose production, producing a greater hyperglycemic response than either hormone alone. These findings established that hormone-induced hyperglycemia is regulated through coordinated endocrine interactions rather than isolated hormonal actions.

Further investigations have expanded the understanding of these mechanisms by demonstrating contributions from extrahepatic tissues. Saccà et al. (1980) reported that both glucagon and epinephrine stimulate renal glucose release in conscious dogs, indicating that the kidney contributes significantly to endogenous glucose production during hormone-induced hyperglycemia. Likewise, studies examining tissue utilization during epinephrine-induced hyperglycemia showed that epinephrine not only increases glucose production but also decreases peripheral glucose utilization while promoting fatty acid oxidation, thereby preserving circulating glucose for glucose-dependent organs. More recently, standardized experimental protocols have improved the reproducibility of hormone-induced hyperglycemia models through optimization of animal selection, hormone dosage, fasting duration, and blood glucose monitoring, increasing their utility in preclinical pharmacological research.

Because of their physiological relevance, reproducibility, and reversibility, epinephrine- and glucagon-induced hyperglycemia models remain valuable experimental tools for studying glucose homeostasis, endocrine regulation, hepatic carbohydrate metabolism, and the pharmacological evaluation of novel antihyperglycemic therapies.

2. Hormonal Regulation of Blood Glucose

Maintenance of blood glucose concentration depends on the coordinated actions of insulin and several counter-regulatory hormones, including glucagon, epinephrine, cortisol, and growth hormone. Under normal physiological conditions, insulin promotes glucose uptake by skeletal muscle and adipose tissue while suppressing hepatic glucose production, thereby maintaining plasma glucose within a narrow physiological range. During fasting, hypoglycemia, exercise, trauma, or acute stress, counter-regulatory hormones increase circulating glucose concentrations by stimulating hepatic glycogenolysis and gluconeogenesis while simultaneously reducing peripheral glucose utilization (Hall &Hall, 2021).

Among these hormones, epinephrine and glucagon produce the most rapid changes in glucose homeostasis and therefore serve as the principal hormones used for experimental induction of transient hyperglycemia. Glucagon is secreted by pancreatic α-cells in response to

Official Website
www.thescienceworld.net
thescienceworldmagazine@gmail.com
Published 15/10/2026

declining plasma glucose concentrations and acts primarily on hepatocytes through glucagon receptors coupled to adenylate cyclase. Activation of the cyclic adenosine monophosphate (cAMP)-protein kinase A signaling pathway stimulates glycogenolysis, enhances gluconeogenesis, inhibits glycogen synthesis, and suppresses glycolysis, resulting in increased hepatic glucose output (Campbell & Drucker, 2015).

In contrast, epinephrine, released from the adrenal medulla during activation of the sympathetic nervous system, exerts broader metabolic effects because adrenergic receptors are widely distributed throughout the liver, pancreas, skeletal muscle, adipose tissue, and kidneys. Besides stimulating hepatic glycogenolysis and gluconeogenesis, epinephrine suppresses insulin secretion through α_2-adrenergic receptor activation, enhances glucagon secretion through β_2-adrenergic receptors, stimulates lipolysis, and reduces insulin-mediated glucose uptake by peripheral tissues (Brunton et al., 2023).

Experimental studies have demonstrated that these hormones function cooperatively rather than independently. Gerich et al. (1976) showed that suppression of glucagon secretion markedly reduced the hyperglycemic response to epinephrine, indicating that pancreatic glucagon is an important mediator of catecholamine-induced glucose production. Similarly, Eigler et al. (1979) demonstrated that combined administration of physiological concentrations of epinephrine and glucagon produced hepatic glucose output substantially greater than that observed with either hormone alone. These findings explain why laboratory models employing combined hormone administration more closely resemble the endocrine responses associated with stress-induced hyperglycemia.

The coordinated regulation of glucose metabolism by epinephrine and glucagon forms the physiological basis for their use in laboratory models. By reproducing the endocrine responses that occur during acute stress while preserving pancreatic β-cell integrity, these models provide an effective means of studying glucose regulation and evaluating pharmacological interventions targeting hepatic glucose production and insulin secretion.

3. Epinephrine-Induced Hyperglycemia

3.1 Physiological Background

Epinephrine (adrenaline) is a catecholamine synthesized in the adrenal medulla and rapidly released into the circulation during activation of the sympathetic nervous system. Physiological stimuli including hypoglycemia, strenuous exercise, trauma, hemorrhage, surgery, and emotional stress increase epinephrine secretion as part of the "fight-or-flight" response. One of its primary metabolic functions is to ensure an adequate supply of glucose to vital organs, particularly the

Official Website
www.thescienceworld.net
thescienceworldmagazine@gmail.com
Published 15/10/2026

brain and skeletal muscle, by rapidly increasing endogenous glucose production and limiting peripheral glucose utilization (Hall & Hall, 2021).

Because epinephrine produces a rapid yet reversible increase in blood glucose concentration without destroying pancreatic β-cells, it has become one of the most widely used hormones for experimental induction of acute hyperglycemia. Compared with chemically induced diabetic models, epinephrine-induced hyperglycemia more closely reproduces the physiological endocrine responses associated with acute stress and is therefore particularly useful for investigating glucose homeostasis, adrenergic pharmacology, and short-term metabolic regulation (Vogel, 2008).

3.2 Mechanism of Epinephrine-Induced Hyperglycemia

The hyperglycemic effect of epinephrine results from coordinated actions on multiple organs, primarily the liver, pancreas, skeletal muscle, adipose tissue, and kidneys. In hepatocytes, activation of β_2-adrenergic receptors stimulates adenylate cyclase, increasing intracellular cAMP concentrations and activating protein kinase A (PKA). PKA phosphorylates phosphorylase kinase, leading to activation of glycogen phosphorylase and rapid degradation of hepatic glycogen into glucose-1-phosphate. Simultaneously, glycogen synthase is inhibited, preventing glycogen synthesis and maximizing glucose release into the circulation (Murray et al., 2022).

As hepatic glycogen stores decline, epinephrine sustains hyperglycemia by stimulating gluconeogenesis. Increased expression of phosphoenolpyruvate carboxykinase, glucose-6-phosphatase, and other gluconeogenic enzymes enhances glucose synthesis from lactate, glycerol, and glucogenic amino acids. Lipolysis in adipose tissue further increases glycerol availability, while skeletal muscle glycogenolysis supplies lactate for hepatic glucose production (Hall & Hall, 2021).

A distinctive feature of epinephrine-induced hyperglycemia is its effect on pancreatic endocrine function. Gerich et al. (1976) demonstrated that epinephrine suppresses insulin secretion through activation of α_2-adrenergic receptors on pancreatic β-cells while simultaneously stimulating glucagon secretion from α-cells via β_2-adrenergic receptor activation. The authors further showed that inhibition of glucagon secretion significantly attenuated the hyperglycemic response to epinephrine, establishing that pancreatic glucagon is a major contributor to catecholamine-induced hyperglycemia rather than merely a secondary hormonal response.

Epinephrine also reduces peripheral glucose utilization by decreasing insulin-mediated glucose uptake in skeletal muscle and adipose tissue. Studies investigating tissue utilization during epinephrine-induced hyperglycemia demonstrated that glucose uptake by skeletal muscle

Official Website
www.thescienceworld.net
thescienceworldmagazine@gmail.com
Published 15/10/2026

decreases despite elevated plasma glucose concentrations, whereas fatty acid oxidation increases substantially. This metabolic shift conserves circulating glucose for glucose-dependent tissues while free fatty acids become the preferred energy substrate for peripheral tissues. Concurrent stimulation of hormone-sensitive lipase increases circulating free fatty acids and glycerol, further supporting hepatic gluconeogenesis and contributing to transient insulin resistance.

In addition to hepatic glucose production, renal glucose release also contributes to the hyperglycemic response. Saccà et al. (1980) demonstrated that epinephrine stimulates renal gluconeogenesis in conscious dogs, indicating that the kidney becomes an important source of endogenous glucose during sustained hormone infusion. These findings expanded the understanding of hormone-induced hyperglycemia by demonstrating coordinated glucose production from both hepatic and renal tissues.

Collectively, enhanced glycogenolysis, increased gluconeogenesis, suppression of insulin secretion, stimulation of glucagon release, decreased peripheral glucose utilization, increased lipolysis, and renal glucose production produce the rapid but reversible hyperglycemia characteristic of epinephrine administration. These integrated physiological responses explain why epinephrine remains one of the most reliable hormones for experimentally inducing acute hyperglycemia in laboratory animals.

4. Glucagon-Induced Hyperglycemia

Glucagon-induced hyperglycemia is a widely used experimental model for investigating hepatic glucose regulation and counter-regulatory hormone action. Glucagon is a peptide hormone secreted by pancreatic α-cells, mainly during conditions of low blood glucose, and its primary function is to increase glucose availability by stimulating glucose production in the liver. After binding to glucagon receptors on hepatocytes, glucagon activates adenylate cyclase, which increases intracellular cyclic adenosine monophosphate (cAMP) levels. This activates protein kinase A (PKA), leading to phosphorylation of enzymes involved in glucose metabolism and promoting hepatic glucose release (Campbell and Drucker, 2015).

The major mechanisms responsible for glucagon-induced hyperglycemia are hepatic glycogenolysis and gluconeogenesis. During glycogenolysis, glucagon activates glycogen phosphorylase, resulting in the breakdown of stored liver glycogen into glucose, which is released into the circulation. Glucagon also enhances gluconeogenesis by increasing the conversion of substrates such as lactate, glycerol, and amino acids into glucose. At the same time, it inhibits glycogen synthesis, shifting liver metabolism toward glucose production rather than storage (Eigler et al., 1979).

Official Website
www.thescienceworld.net
thescienceworldmagazine@gmail.com
Published 15/10/2026

Experimental studies by Eigler et al. (1979) demonstrated that glucagon has a major role in increasing hepatic glucose output and producing hyperglycemia through activation of liver glucose-producing pathways. Their findings supported the concept that excessive glucagon activity contributes to abnormal glucose regulation. Similarly, Campbell and Drucker (2015) described glucagon signaling as an important regulator of energy metabolism and emphasized its contribution to metabolic diseases such as diabetes mellitus, where increased glucagon action promotes excessive hepatic glucose production.

Compared with epinephrine, glucagon produces a more direct hepatic response because its primary target is the liver. It increases blood glucose mainly by stimulating endogenous glucose production without causing major changes in peripheral glucose uptake. Due to its predictable and reproducible effect, glucagon administration is commonly used in laboratory models to study glucose homeostasis, insulin function, and metabolic disorders.

5. Synergistic Interaction Between Epinephrine and Glucagon

Epinephrine and glucagon interact synergistically to regulate blood glucose during stress, fasting, and increased energy demand. Both hormones act as counter-regulatory hormones that oppose insulin action and increase glucose availability. Although they stimulate similar metabolic pathways, their combined effects produce a greater increase in blood glucose compared with administration of either hormone alone (Gerich et al., 1979).

Glucagon primarily increases hepatic glucose production by activating glucagon receptors and stimulating cAMP-dependent signaling pathways. Epinephrine enhances this response through activation of adrenergic receptors in the liver and peripheral tissues. Epinephrine stimulates glycogenolysis, increases gluconeogenesis, and decreases insulin-mediated glucose uptake by skeletal muscle, resulting in elevated circulating glucose levels (Saccà et al., 1983).

The synergistic interaction between these hormones is mainly due to their complementary actions. Glucagon provides a strong hepatic signal for glucose production, while epinephrine not only enhances hepatic glucose release but also reduces peripheral glucose utilization. Studies by Gerich et al. (1979) showed that simultaneous elevation of epinephrine and glucagon produces an amplified hyperglycemic response because both hormones increase hepatic glucose output through overlapping signaling mechanisms. Furthermore, Shamoon et al. (1980) demonstrated that counter-regulatory hormone responses play an important role in maintaining glucose levels during metabolic stress.

The combined epinephrine–glucagon model is therefore useful for studying stress-induced hyperglycemia and abnormalities in hormonal control of glucose metabolism. It provides a

Official Website
www.thescienceworld.net
thescienceworldmagazine@gmail.com
Published 15/10/2026

physiological model for examining interactions between hepatic glucose production, insulin suppression, and peripheral glucose disposal.

6. Experimental Methodology and Laboratory Models

Experimental models of epinephrine- and glucagon-induced hyperglycemia are commonly used to investigate hormonal regulation of glucose metabolism. Animal models, particularly rats and mice, are frequently used because they provide well-established systems for studying endocrine and metabolic responses. These models help researchers evaluate changes in blood glucose concentration, hormone interactions, and the effectiveness of glucose-lowering therapies.

In a typical experimental procedure, animals are often fasted before hormone administration to obtain stable baseline glucose levels. Epinephrine, glucagon, or a combination of both hormones is administered through routes such as intraperitoneal or intravenous injection. Blood samples are collected at specific time intervals, and glucose concentrations are measured using enzymatic glucose assays, glucose oxidase methods, or blood glucose monitoring devices. The increase in blood glucose after hormone administration is used to assess the hyperglycemic response.

Experimental Methodology for epinephrine

Laboratory animals, particularly Wistar rats, Sprague-Dawley rats, Swiss albino mice, and rabbits, are commonly employed for epinephrine-induced hyperglycemia studies. Animals are fasted overnight (12–18 hours) while allowing free access to water to stabilize basal glucose concentrations.

Epinephrine is generally administered subcutaneously or intraperitoneally at doses ranging from 0.1 to 0.5 mg/kg body weight, although dosing may vary according to species and study design. Baseline blood glucose is measured before hormone administration. Subsequent measurements are recorded at intervals of 15, 30, 60, 90, and 120 minutes using glucometers or automated biochemical analyzers.

Peak hyperglycemia generally occurs between 20 and 45 minutes after injection and gradually returns toward baseline within approximately two hours as circulating catecholamines are metabolized by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO) (Vogel, 2008).

Experimental Methodology for Glucagon

Experimental animals are fasted overnight before glucagon administration to maximize hepatic glycogen responsiveness. Glucagon is administered intravenously, intraperitoneally, or subcutaneously at doses generally ranging between 50 and 200 µg/kg body weight.

Official Website
www.thescienceworld.net
thescienceworldmagazine@gmail.com
Published 15/10/2026

Blood glucose concentrations are determined before administration and periodically afterward at intervals of 15, 30, 60, and 120 minutes. Hyperglycemia typically peaks within 20–30 minutes and gradually subsides as glucagon is degraded by hepatic and renal metabolism (Vogel, 2008).

The magnitude of induced hyperglycemia depends on several factors, including hormone dose, route of administration, animal species, nutritional state, liver glycogen content, and insulin sensitivity. Tissue-based studies have also been used to examine changes in glucose production and utilization at the cellular level. These experimental approaches provide important information about hepatic glucose regulation and the mechanisms involved in stress-related metabolic changes (Gerich et al., 1979; Saccà et al., 1983).

Overall, epinephrine- and glucagon-induced hyperglycemia models are valuable tools in metabolic research because they allow controlled investigation of counter-regulatory hormone actions and provide platforms for studying diabetes, insulin resistance, and potential therapeutic interventions.

7. Applications

Epinephrine- and glucagon-induced hyperglycemia models have wide applications in experimental physiology, endocrinology, and metabolic research. These models are particularly useful for understanding the mechanisms involved in glucose regulation and the role of counter-regulatory hormones under normal and pathological conditions. By artificially increasing blood glucose levels through hormone administration, researchers can study changes in hepatic glucose production, insulin secretion, and tissue glucose utilization (Gerich et al., 1979).

One of the major applications of these models is in diabetes mellitus research. Abnormal regulation of glucagon and epinephrine contributes to increased hepatic glucose output and impaired glucose homeostasis in diabetic conditions. Glucagon administration is frequently used to examine pancreatic α-cell function, hepatic glucose metabolism, and the balance between insulin and glucagon actions. These models also help in understanding stress-induced hyperglycemia, where increased catecholamine release causes elevated blood glucose levels (Campbell and Drucker, 2015).

These experimental models are also important in drug development and evaluation. New antidiabetic agents, insulin sensitizers, and drugs targeting hepatic glucose production can be tested using hormone-induced hyperglycemia models. The ability of a compound to reduce hormone-induced increases in blood glucose provides information about its effectiveness in controlling metabolic disturbances. In addition, these models are useful for studying the actions of drugs that influence glucagon signaling or adrenergic pathways (Drucker, 2016).

Official Website
www.thescienceworld.net
thescienceworldmagazine@gmail.com
Published 15/10/2026

Another important application is in the study of stress metabolism and hormonal interactions. During stress conditions such as trauma, infection, or intense exercise, epinephrine and glucagon work together to maintain glucose supply to essential tissues. Experimental induction of hyperglycemia helps researchers understand these adaptive responses and the mechanisms involved in maintaining energy balance (Saccà et al., 1983).

8. Comparison Between Epinephrine- and Glucagon-Induced Hyperglycemia

Epinephrine- and glucagon-induced hyperglycemia both result from increased glucose availability in the bloodstream, but their mechanisms and metabolic effects differ. Glucagon mainly acts on the liver to stimulate glucose production, whereas epinephrine produces a broader metabolic response involving the liver, skeletal muscle, and adipose tissue. Both hormones activate intracellular signaling pathways involving cyclic AMP (cAMP) and protein kinase A (PKA), leading to increased glucose release (Eigler et al., 1979).

Glucagon primarily increases blood glucose by stimulating hepatic glycogenolysis and gluconeogenesis. Its action is highly specific to hepatocytes because glucagon receptors are mainly expressed in the liver. Therefore, glucagon-induced hyperglycemia reflects changes in endogenous hepatic glucose production. In contrast, epinephrine acts through α- and β-adrenergic receptors, stimulating hepatic glycogen breakdown while also decreasing insulin-mediated glucose uptake in peripheral tissues such as skeletal muscle (Gerich et al., 1979).

The onset and duration of hyperglycemia also differ between the two hormones. Epinephrine produces a rapid increase in blood glucose because of its immediate adrenergic action during stress responses, but the effect is generally shorter in duration. Glucagon produces a more sustained elevation of blood glucose because it directly promotes hepatic glucose production. When both hormones are administered together, their effects are amplified, producing a stronger hyperglycemic response due to their complementary actions (Saccà et al., 1983).

Feature	**Epinephrine-Induced Hyperglycemia**	**Glucagon-Induced Hyperglycemia**
Hormone source	Adrenal medulla	Pancreatic α-cells
Main target	Liver and peripheral tissues	Mainly liver
Primary action	Glycogenolysis and reduced glucose uptake	Glycogenolysis and gluconeogenesis
Receptors involved	Adrenergic receptors	Glucagon receptors
Response type	Stress-related	Fasting/metabolic regulation

Official Website
www.thescienceworld.net
thescienceworldmagazine@gmail.com
Published 15/10/2026

Duration	Shorter effect	More sustained effect
Peripheral effects	Strong effect on glucose utilization	Minimal peripheral effect

9. Advantages and Limitations

Advantages

Epinephrine- and glucagon-induced hyperglycemia models provide several advantages for studying glucose metabolism. They are simple, reproducible, and allow researchers to induce controlled increases in blood glucose levels within a short period. These models help clarify the physiological roles of counter-regulatory hormones and provide insight into mechanisms controlling hepatic glucose production (Gerich et al., 1979).

Another major advantage is their usefulness in evaluating metabolic disorders and therapeutic approaches. These models can be used to investigate insulin resistance, impaired hormonal regulation, and the effectiveness of antidiabetic drugs. Because epinephrine and glucagon represent natural regulators of glucose homeostasis, their administration provides a physiologically relevant approach for studying metabolic responses (Campbell and Drucker, 2015).

Limitations

Despite their usefulness, these models have certain limitations. The hormone doses used in experimental studies may sometimes exceed physiological concentrations, which can produce exaggerated metabolic responses. Acute hormone-induced hyperglycemia does not completely reproduce chronic conditions such as long-term diabetes mellitus or metabolic syndrome.

Additionally, responses may vary depending on animal species, age, nutritional status, hormone sensitivity, and experimental conditions. Differences between animal and human glucose metabolism must also be considered when interpreting results. Epinephrine administration may influence cardiovascular function and stress pathways, which can introduce additional variables into experiments.

Therefore, while epinephrine- and glucagon-induced hyperglycemia models are valuable research tools, they should be interpreted carefully and ideally combined with other metabolic studies to obtain a complete understanding of glucose regulation (Shamoon et al., 1980).

10. Conclusion

Epinephrine- and glucagon-induced hyperglycemia models are important experimental approaches for understanding the hormonal regulation of blood glucose and the mechanisms involved in metabolic adaptation. Both hormones act as major counter-regulatory factors that increase glucose availability during fasting, stress, and increased energy demand. Although they

Official Website
www.thescienceworld.net
thescienceworldmagazine@gmail.com
Published 15/10/2026

produce similar outcomes, their mechanisms of action differ, with glucagon mainly promoting hepatic glucose production and epinephrine producing both hepatic and peripheral metabolic effects.

Glucagon-induced hyperglycemia occurs primarily through stimulation of hepatic glycogenolysis and gluconeogenesis, while epinephrine enhances glucose availability through adrenergic activation, increased hepatic glucose output, and reduced peripheral glucose utilization. The interaction between these hormones produces a stronger hyperglycemic response, demonstrating the importance of hormonal coordination in maintaining glucose homeostasis (Gerich et al., 1979; Saccà et al., 1983).

Experimental studies using these models have contributed significantly to the understanding of diabetes, stress-induced hyperglycemia, insulin resistance, and metabolic disorders. Research by Eigler et al. (1979) and Campbell and Drucker (2015) emphasized the central role of glucagon signaling in glucose regulation, while studies on epinephrine responses highlighted the importance of stress hormones in metabolic control. Despite certain limitations, these models remain valuable tools for investigating glucose metabolism and evaluating potential therapeutic strategies.

References:

Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (Eds.). (2023). *Goodman & Gilman's the pharmacological basis of therapeutics* (14th ed.). McGraw-Hill.

Campbell, J. E., & Drucker, D. J. (2015). Islet α cells and glucagon—Critical regulators of energy homeostasis. *Nature Reviews Endocrinology, 11*(6), 329–338. https://doi.org/10.1038/nrendo.2015.51

Eigler, N., Saccà, L., & Sherwin, R. S. (1979). Interaction of glucagon and epinephrine in the control of hepatic glucose production in the conscious dog. *Metabolism, 28*(11), 1149–1156.

Gerich, J. E., Lorenzi, M., Tsalikian, E., & Karam, J. H. (1976). Studies on the mechanism of epinephrine-induced hyperglycemia in man: Evidence for participation of pancreatic glucagon secretion. *The Journal of Clinical Investigation, 57*, 875–884. https://doi.org/10.1172/JCI108322

Hall, J. E., & Hall, M. E. (2021). *Guyton and Hall textbook of medical physiology* (14th ed.). Elsevier.

Murray, R. K., Bender, D. A., Botham, K. M., Kennelly, P. J., Rodwell, V. W., & Weil, P. A. (2022). *Harper's illustrated biochemistry* (32nd ed.). McGraw-Hill.

Saccà, L., Hendler, R., & Sherwin, R. S. (1980). Effects of hyperglycemia, glucagon, and epinephrine on renal glucose release in the conscious dog. *Diabetes, 29*, 790–795.

Shamoon, H., Hendler, R., & Sherwin, R. S. (1981). Synergistic interactions of physiologic increments of glucagon, epinephrine, and cortisol in the dog: A model for stress-induced hyperglycemia. *The Journal of Clinical Investigation, 67*, 1230–1237. https://doi.org/10.1172/JCI110169

Official Website
www.thescienceworld.net
thescienceworldmagazine@gmail.com
Published 15/10/2026

Unger, R. H., & Cherrington, A. D. (2012). Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover. *The Journal of Clinical Investigation, 122*(1), 4–12. https://doi.org/10.1172/JCI60016

Vogel, H. G. (Ed.). (2008). *Drug discovery and evaluation: Pharmacological assays* (3rd ed.). Springer.